Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Retained Earnings (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Retained Earnings for 12 consecutive years, with -$195.1 million as the latest value for Q1 2026.

  • For Q1 2026, Retained Earnings rose 60.72% year-over-year to -$195.1 million; the TTM value through Mar 2026 reached -$195.1 million, up 60.72%, while the annual FY2025 figure was -$171.8 million, N/A changed from the prior year.
  • Retained Earnings hit -$195.1 million in Q1 2026 for Crescent Biopharma, down from -$171.8 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$54.8 million in Q2 2025 and bottomed at -$496.7 million in Q1 2025.
  • Average Retained Earnings over 5 years is -$363.7 million, with a median of -$424.7 million recorded in 2022.
  • Year-over-year, Retained Earnings decreased 19.71% in 2022 and then skyrocketed 88.52% in 2025.
  • Crescent Biopharma's Retained Earnings stood at -$419.6 million in 2022, then fell by 8.79% to -$456.5 million in 2023, then fell by 6.72% to -$487.1 million in 2024, then surged by 64.73% to -$171.8 million in 2025, then fell by 13.56% to -$195.1 million in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$195.1 million, -$171.8 million, and -$79.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.